Crossmark

Treatment of knee osteoarthritis with intra-articular injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE®: a phase I/II, randomized, active-control, single-blind, multiple-center clinical trial

Crossref DOI link: https://doi.org/10.1186/s13287-021-02631-z

Published Online: 2021-10-30

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chen, Cheng-Fong

Hu, Chih-Chien

Wu, Chen-Te

Wu, Hung-Ta H.

Chang, Chun-Shin

Hung, Yi-Pei

Tsai, Chia-Chu

Chang, Yuhan http://orcid.org/0000-0002-7369-0300
Funding

Funding for this research was provided by:

unicocell biomed co. ltd.

ministry of economic affairs (105-EC-17-A-22-I5-0007)
License Information

Text and Data Mining valid from 2021-10-30

Version of Record valid from 2021-10-30
More Information

Article History

Received: 1 August 2021

Accepted: 4 October 2021

First Online: 30 October 2021

Declarations

:

: The protocol of the study was approved by the Institutional Review Board to the tenets of the Declaration of Helsinki. There were two study sites in this trial, including Linkou Chang Gung Memorial Hospital and Taipei Veterans General Hospital in Taiwan. The official ethical approval numbers of the study were 104-1182A (CGMF-IRB) and 2017–04-005A (VGHTPE-IRB). The study was registered at ExternalRef removed (NCT02784964).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below